Virtus Lifesci Biotech Clinical Trials ETF (BBC) Stock Price, Quote & News

Company Profile

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Phone: (212) 593-4383

ZacksResearch Oct. 20 at 12:30 PM

Biotech’s back — and the rally looks real. 💥 $IBB, $ARKG, $SBIO, $BBC, and $BBP are soaring as Fed rate cut optimism, a wave of FDA approvals, fresh deals, and lower valuations spark major momentum across the sector. Find out what’s fueling biotech’s 2025 comeback 👉 https://www.zacks.com/stock/news/2772024/biotech-etfs-bounce-back-in-2025-heres-why?cid=sm-stocktwits-2-2772024-teaser-16718&ADID=SYND_STOCKTWITS_TWEET_2_2772024_TEASER_16718

0 · Reply

ZacksResearch Oct. 16 at 5:12 PM

Trade tensions spike, but these ETFs are shining! 🚀 🌿 $MSOS up 5.8% fueled by U.S. cannabis legalization hopes and pro-CBD stance. 🥇 $SGDJ gains with gold's safe-haven appeal amid trade tensions and geopolitical risks. 🔬 $BBC rebounds on medical innovation, decent valuation, and favorable drug-pricing deals. See why these sectors stand out amid volatility 👇 https://www.zacks.com/stock/news/2769856/trade-war-or-not-specific-industry-etfs-are-in-sweet-spots?cid=sm-stocktwits-2-2769856-body-16469&ADID=SYND_STOCKTWITS_TWEET_2_2769856_BODY_16469

0 · Reply

dogDazeSummer Oct. 16 at 1:00 PM

$IFRX great to see $XBI $BBC making new highs on big volume. Still a long way from ATH, but clearly good data is being rightfully rewarded, $PRAX out with strong P3 today good for entire sector. Glad we’re in a bullish phase vs 6 months ago releasing data.

3 · Reply

Reanimated666 Oct. 15 at 4:29 PM

$BBC Took a little off my position here It ran very nicely and because of the aggressiveness of the Holding, I took the prophet

0 · Reply

macroaxis Oct. 13 at 5:29 AM

$BBC - Virtus LifeSci Approaching Max Pain Point, Potential for Price Reversal https://www.macroaxis.com/stock-options/BBC/Virtus-LifeSci-Biotech?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

dogDazeSummer Sep. 26 at 11:47 PM

$IFRX Friendly reminder of Inflarx patent obtained in conjunction with Roche’s tocilizumab. Tocilizumab, originally approved as Actemra, has received FDA approval for various autoimmune and inflammatory conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis. It is also approved for giant cell arteritis (GCA), COVID-19 in hospitalized patients. Ask yourself why Inflarx would obtain a patent for combined treatment of vilo + tocil—-and also if they wld do this—-> without first collaborating/ obtaining green light from $RHHBY $XBI $BBC

4 · Reply

Reanimated666 Sep. 24 at 3:56 PM

$BBC -Performing well

0 · Reply

dogDazeSummer Sep. 17 at 12:02 PM

$IFRX Steifel out with bullish report on biotech M&A. $1.2T on sidelines $XBI $BBC

2 · Reply

Reanimated666 Sep. 10 at 3:23 PM

$BBC Got to be in it to win it

0 · Reply

ZacksResearch Sep. 9 at 1:30 PM

Last week’s ETF winners you need to see 👀 $BWET, $GOEX, $SLVP, $LIT and $BBC all topped the charts — powered by sector strength, safe-haven flows, and renewed Fed rate cut hopes 📈. See the full performance breakdown here 👉 https://www.zacks.com/stock/news/2748482/best-performing-etfs-of-last-week?cid=sm-stocktwits-2-2748482-teaser-11447&ADID=SYND_STOCKTWITS_TWEET_2_2748482_TEASER_11447

0 · Reply

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBH BBP BIB BIS BMED

Feb 25, 2025, 11:06 AM EST - 8 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBH BBP BIB

Mar 16, 2023, 3:51 PM EDT - 2 years ago

The Fall Of SVB: What It Means For Healthcare Startups

BBH FBT IBB IHE IHF IHI IYH

Jan 11, 2023, 6:09 PM EST - 3 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG ARKG BBH BBP BMED CNCR FBT

Aug 26, 2022, 1:24 AM EDT - 3 years ago

What The Inflation Reduction Act Means For Drug Prices

BBH IBB IHE IHF IHI IYH PBE

Aug 19, 2021, 7:51 PM EDT - 4 years ago

Should Investors Follow Private Equity into Life Sciences?

BNTX CNCR PFE

Jun 10, 2021, 9:30 AM EDT - 4 years ago

Biotechs Ready To Roar

ANVS ARVN AVXL BBH BBP BHVN BIIB

Apr 15, 2021, 9:31 AM EDT - 4 years ago

Moving Beyond COVID In Biopharma

BBH BBP CNCR FBT FTXH GNOM HQL

Jul 7, 2020, 12:22 PM EDT - 5 years ago

Novavax's 30% surge boosts biotech ETFs to best day in weeks

NVAX

Jun 30, 2020, 3:46 PM EDT - 5 years ago

3 ETFs With Q2 Gains Of At Least 30%

ACES ARGT

Jun 6, 2020, 3:19 AM EDT - 5 years ago

The Market Speaks: 3 Mega Trends Are Happening

AMT BOTZ CCI ROBO SBAC

May 7, 2020, 11:36 AM EDT - 5 years ago

3 Biotech ETFs Up 10% Or More Over The Last Month

ARKG

Mar 10, 2020, 5:47 PM EDT - 6 years ago

Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be

Feb 13, 2020, 9:19 AM EST - 6 years ago

Best Growth ETFs for Q1 2020

VGT XLK

Feb 10, 2020, 1:40 PM EST - 6 years ago

Best Healthcare ETFs for Q1 2020

KURE SBIO

Dec 28, 2019, 6:02 PM EST - 6 years ago

5 Best ETFs Of 2019

GOAU PALL TAN XSD

Dec 9, 2019, 7:25 AM EST - 6 years ago

There's A Really Good Chance You Missed One Of The Year's Best ETFs

ZacksResearch Oct. 20 at 12:30 PM

0 · Reply

ZacksResearch Oct. 16 at 5:12 PM

0 · Reply

dogDazeSummer Oct. 16 at 1:00 PM

3 · Reply

Reanimated666 Oct. 15 at 4:29 PM

$BBC Took a little off my position here It ran very nicely and because of the aggressiveness of the Holding, I took the prophet

0 · Reply

macroaxis Oct. 13 at 5:29 AM

$BBC - Virtus LifeSci Approaching Max Pain Point, Potential for Price Reversal https://www.macroaxis.com/stock-options/BBC/Virtus-LifeSci-Biotech?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

dogDazeSummer Sep. 26 at 11:47 PM

4 · Reply

Reanimated666 Sep. 24 at 3:56 PM

$BBC -Performing well

0 · Reply

dogDazeSummer Sep. 17 at 12:02 PM

$IFRX Steifel out with bullish report on biotech M&A. $1.2T on sidelines $XBI $BBC

2 · Reply

Reanimated666 Sep. 10 at 3:23 PM

$BBC Got to be in it to win it

0 · Reply

ZacksResearch Sep. 9 at 1:30 PM

0 · Reply

sshd Sep. 3 at 11:33 PM

$BBC i love bbc

1 · Reply

ComradeKomisar Aug. 6 at 7:16 PM

$EBS Yeah, actually, it's Emergent that deserves the Nobel. Be that is it may, the biotech industry lobby remains cowed and conciliatory based on this headline from StatNews. $XBI $IBB $BBC

0 · Reply

macroaxis May. 23 at 5:10 AM

$BBC - Implied volatility is shrinking to 0.56 for Virtus LifeSci https://www.macroaxis.com/stock-options/BBC/Virtus-LifeSci-Biotech?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

NorthShoreTrader2021 May. 12 at 2:17 AM

$LABU It is down 3% overnight on robinhood. $IBB, $XBI, $BBC

0 · Reply

geroscience May. 7 at 8:40 AM

$LCTX $XBI $BBC Thoughts on new FDA CBER head Vinay Prasad: Having read many of his papers/watched his YT over the years, if he is to be consistent with his beliefs then this will be bearish for biotech as a sector, consistent with the market selloff today. He is against surrogate endpoints (in absence of clinically relevant functional benefit shown in adequately powered trials) and strongly errs on the side of primum non nocere 'do no harm', even if this means one delays approval of a *potentially* beneficial drug. The counterargument to this is that cancer patients may die waiting for a drug that could have been effective - the problem with this, and I am sympathetic to Vinay's view, is that most investigational cancer drugs fail to improve survival and/or are toxic, so delaying approval for more robust pivotal trial evidence is net good for society (and taxpayers). However, biotechs relying on accelerated approval will be hampered (simply consider how NPV changes w/ delayed revs).

1 · Reply

Pika_Capital Apr. 21 at 2:21 PM

$XBI $BBC you are about to miss the biggest bull market in biotech history from these depressed 💀 levels

1 · Reply

frontiere Apr. 11 at 9:46 AM

$VIVS Organovo — bought lows sold yesterday below $3 unfortunately, rebuying now — spike from $2 to $3.6 (low-ish volume, albeit) was also due to this FDA new plan phasing out animal studies? 👇Due to Organovo’s organoid sold to LLY? Btw + FDA roadmap attached to that PR https://www.fda.gov/media/186092/download : 👍 gives more color on the challenges (low predictivity and high NHP cost) and the alternative methods. 👍openness to new tools & models while maintaining the integrity. It guides more on the "reduce and refine" (e.g. 3-month GLP tox + NAMs), less on "replace". 👍GLP tox (dog & primate) is one of key milestones in preclinical dev. The blocker from NHP cost as well as availability seems to be what triggered this roadmap. The trade war made it much worse. $XBI $XLV $BBC DNA CERT SLP SDGR CRL

1 · Reply

TwoThirdsProbablyDown Apr. 4 at 2:49 PM

$SGMO in line with $BBC etfs that track clinical stage biotechs, but still annoying as hell. SP (high or low) remains arbitrary until we see terms of Fabry deal. I’m wondering if that stupid Barclays event for the quarter had the sole purpose of messaging to potl Fabry partners that SM was going to do Capsid deals and not cave to their hardball tactics.

1 · Reply

ComradeKomisar Mar. 31 at 8:35 PM

$EBS v $BBC EBS is trading sub-clinically LMAO since earnings, and clinically since Feb 18. The market thinks we have no products, no pipe, no revenue.

2 · Reply

alexpitti Mar. 26 at 11:04 PM

every day is a new beat down $XBI $BBC

0 · Reply

AlphaTuna Mar. 20 at 10:40 PM

Highest Volume Rated ETFs Per 3/20/2025’s Close: 1 – $PSMR 2 – $MYCL 3 – $MYCM 4 – $MYCK 5 – $MYCN 6 – $XBJL 7 – $KURE 8 – $TJUL 9 – $LLDR 10 – $BBC https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-3-20-2025/

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	N/A
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A